PMID- 37602318
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230823
IS  - 2468-0540 (Electronic)
IS  - 2468-0540 (Linking)
VI  - 8
IP  - 4
DP  - 2023 Dec
TI  - A novel microRNA panel exhibited significant potential in evaluating the 
      progression of laryngeal squamous cell carcinoma.
PG  - 550-561
LID - 10.1016/j.ncrna.2023.08.001 [doi]
AB  - BACKGROUND: Laryngeal squamous cell carcinoma (LSCC) is a common cancer of the 
      head and neck in humans. The 5-years survival rate of patients with LSCC have 
      declined in the past four decades. microRNAs (miRNAs) has been reported to be 
      capable of predicting the prognosis outcomes of patients with different cancers. 
      However, there are no reports on the usage of multi-miRNAs model as signature for 
      the diagnosis or prognosis of LSCC. METHODS: To establish the miRNAs 
      expression-associated model for diagnosis, prognosis prediction and aided therapy 
      of patients with LSCC, the present study enrolled 107 patients with LSCC in 
      clinic and obtained 117 LSCC samples data from TCGA database for evaluation, 
      respectively. Next generation sequencing (NGS), raw data processing, the least 
      absolute shrinkage and selection operator algorithm, Cox regression analysis, 
      construction of nomogram and cell function assays (including proliferation, 
      migration and invasion assays) were sequentially performed. RESULTS: There were 
      massively dysregulated miRNAs in the LSCC compared to normal tissues. A 
      six-miRNAs signature consists of miR-137-3p, miR-3934-5p, miR-1276, miR-129-5p, 
      miR-7-5p and miR-105-5p was built for prognosis prediction of LSCC patients. The 
      six-miRNAs signature is strongly associated with the poor overall survival (OS, 
      p = 2.5e-05, HR: 4.30 [2.20-8.50]), progression free interval (PFI, p = 0.025, 
      HR: 1.94 [1.08-3.46]) and disease specific survival (DSS, p = 1.1e-05, HR: 5.00 
      [2.50-10.00]). A nomogram for prediction of 2-, 3- and 5-years OS was also 
      developed based on the six-miRNAs signature and clinical features. Furthermore, 
      blocking the function of each of the six miRNAs inhibited proliferation, invasion 
      and migration of LSCC cells. CONCLUSIONS: The performance of six-miRNAs signature 
      described in the current study demonstrated remarkable potential for progression 
      assessment of LSCC. Moreover, the six-miRNAs signature may serve as predictive 
      tool for prognosis and therapeutic targets of LSCC in clinic.
CI  - (c) 2023 The Authors.
FAU - Zhang, Linshi
AU  - Zhang L
AD  - Department of Thyroid Surgery, The Second Affiliated Hospital of Zhejiang 
      University School of Medicine, Hangzhou, 310009, Zhejiang, PR China.
FAU - Zhang, Zhe
AU  - Zhang Z
AD  - Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, First Hospital 
      of Shanxi Medical University, Taiyuan, 030001, Shanxi, PR China.
AD  - Shenzhen Eye Institute, Shenzhen Eye Hospital, Shenzhen, 518040, Guangdong, PR 
      China.
FAU - Zheng, Xiwang
AU  - Zheng X
AD  - Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, First Hospital 
      of Shanxi Medical University, Taiyuan, 030001, Shanxi, PR China.
FAU - Lu, Yan
AU  - Lu Y
AD  - Department of Otolaryngology Head & Neck Surgery, First Hospital of Jinzhou 
      Medical University, Jinzhou, 121011, Liaoning, PR China.
FAU - Dai, Li
AU  - Dai L
AD  - Department of Otolaryngology Head & Neck Surgery, Shanxi Bethune Hospital, 
      Taiyuan, 030032, Shanxi, PR China.
FAU - Li, Wenqi
AU  - Li W
AD  - Department of Biochemistry and Molecular Biology, School of Basic Medical 
      Sciences, Southern Medical University, Guangzhou, 510515, Guangdong, PR China.
FAU - Liu, Hui
AU  - Liu H
AD  - Department of Hepatobiliary Surgery, Shenzhen University General Hospital & 
      Shenzhen University Clinical Medical Academy Center, Shenzhen University, 
      Shenzhen, 518055, Guangdong, PR China.
FAU - Wen, Shuxin
AU  - Wen S
AD  - Department of Otolaryngology Head & Neck Surgery, Shanxi Bethune Hospital, 
      Taiyuan, 030032, Shanxi, PR China.
FAU - Xie, Qiuping
AU  - Xie Q
AD  - Department of Thyroid Surgery, The Second Affiliated Hospital of Zhejiang 
      University School of Medicine, Hangzhou, 310009, Zhejiang, PR China.
FAU - Zhang, Xiangmin
AU  - Zhang X
AD  - Department of Otolaryngology Head & Neck Surgery, Longgang Ear-Nose-Throat 
      Hospital, Shenzhen, 518172, Guangdong, PR China.
AD  - Shenzhen Institute of Otolaryngology & Key Laboratory of Otolaryngology, Longgang 
      Ear-Nose-Throat Hospital, Shenzhen, 518172, Guangdong, PR China.
FAU - Wang, Ping
AU  - Wang P
AD  - Department of Thyroid Surgery, The Second Affiliated Hospital of Zhejiang 
      University School of Medicine, Hangzhou, 310009, Zhejiang, PR China.
FAU - Wu, Yongyan
AU  - Wu Y
AD  - Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, First Hospital 
      of Shanxi Medical University, Taiyuan, 030001, Shanxi, PR China.
AD  - Department of Otolaryngology Head & Neck Surgery, Longgang Ear-Nose-Throat 
      Hospital, Shenzhen, 518172, Guangdong, PR China.
AD  - Shenzhen Institute of Otolaryngology & Key Laboratory of Otolaryngology, Longgang 
      Ear-Nose-Throat Hospital, Shenzhen, 518172, Guangdong, PR China.
FAU - Gao, Wei
AU  - Gao W
AD  - Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, First Hospital 
      of Shanxi Medical University, Taiyuan, 030001, Shanxi, PR China.
AD  - Department of Otolaryngology Head & Neck Surgery, Longgang Ear-Nose-Throat 
      Hospital, Shenzhen, 518172, Guangdong, PR China.
AD  - Shenzhen Institute of Otolaryngology & Key Laboratory of Otolaryngology, Longgang 
      Ear-Nose-Throat Hospital, Shenzhen, 518172, Guangdong, PR China.
LA  - eng
PT  - Journal Article
DEP - 20230804
PL  - Netherlands
TA  - Noncoding RNA Res
JT  - Non-coding RNA research
JID - 101688191
PMC - PMC10432973
OTO - NOTNLM
OT  - Laryngeal squamous cell carcinoma
OT  - MicroRNA
OT  - Molecular biomarkers
OT  - Oncogene
OT  - Otorhinolaryngology Head and Neck Surgery
OT  - Overall survival
OT  - Prognosis prediction
COIS- The authors declare that they have no competing interests.
EDAT- 2023/08/21 06:43
MHDA- 2023/08/21 06:44
PMCR- 2023/08/04
CRDT- 2023/08/21 05:12
PHST- 2023/06/07 00:00 [received]
PHST- 2023/08/02 00:00 [revised]
PHST- 2023/08/02 00:00 [accepted]
PHST- 2023/08/21 06:44 [medline]
PHST- 2023/08/21 06:43 [pubmed]
PHST- 2023/08/21 05:12 [entrez]
PHST- 2023/08/04 00:00 [pmc-release]
AID - S2468-0540(23)00048-3 [pii]
AID - 10.1016/j.ncrna.2023.08.001 [doi]
PST - epublish
SO  - Noncoding RNA Res. 2023 Aug 4;8(4):550-561. doi: 10.1016/j.ncrna.2023.08.001. 
      eCollection 2023 Dec.